Independent Financial Information Made Easy
The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.
Open: 354.95 Close: 353.04 Change: -1.91
The game is changing. There is a new strategy to evaluate Vertex Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, price, stock, Incorporated, VRTX, Wall, …
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.
Wall Street analysts predict that Vertex Pharmaceuticals s share price could reach $380.77 by Nov 22, 2024. Wall Street analyst estimates that VRTXs share price will reach a potential upside of 7.85% from current $353.04 USD today.
Vertex Pharmaceuticals Inc. per Employee $1.994M P/E Ratio 26.50 EPS $13.32 Yield N/A Dividend N-A Ex-Dividend Date 10/31/23 % of Float Shorted 1.01% Average Volume 1.15M Performance. Vertex Pharmaceuticals Incorporated (VRTX) stock price, news, quote & history - yahoo finance. Vertex pharmaceuticals incorporated (vrtx) stock. stock price is 353.04 USD today. The stock price of VRTX is 353.04 USD. Vertex Pharmaceuticals is offering a two-year Clinical and Quantitative Pharmacology PharmD fellowship in Boston, MA starting July 2024. Wall Street analysts predict that Vertex Pharmaceuticals s share price could reach $380.77 by Nov 22, 2024. Wall Street analyst estimates that VRTXs share price will reach a potential upside of 7.85% from current $353.04. Vertex Pharmaceuticals Incorporated is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. The company reported earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92. European Commission approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 through 5. Vertex missed Wall Street estimates for third-quarter sales on Monday. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that E. vertex pharmaceuticals wins innovation award - wsj.
"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, price, stock, Incorporated, VRTX, Wall, and the most common words in the summary are: vertex, pharmaceutical, stock, job, market, vrtx, price, . One of the sentences in the summary was: Wall Street analyst estimates that VRTXs share price will reach a potential upside of 7.85% from current $353.04 USD today.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #job #market #vrtx #price.
Read more →Open: 412.34 Close: 413.59 Change: 1.25
Read more →Open: 421.77 Close: 419.63 Change: -2.14
Read more →Open: 425.96 Close: 422.91 Change: -3.05
Read more →Open: 405.0 Close: 410.91 Change: 5.91
Read more →Open: 353.95 Close: 350.19 Change: -3.76
Read more →Open: 373.16 Close: 378.35 Change: 5.19
Read more →Open: 364.95 Close: 369.33 Change: 4.38
Read more →Open: 361.46 Close: 365.25 Change: 3.79
Read more →Open: 343.4 Close: 344.82 Change: 1.42
Read more →Open: 351.42 Close: 347.74 Change: -3.68
Read more →Open: 342.63 Close: 340.54 Change: -2.09
Read more →Open: 330.92 Close: 332.63 Change: 1.71
Read more →Open: 343.29 Close: 344.83 Change: 1.54
Read more →Open: 421.77 Close: 419.63 Change: -2.14
Read more →Open: 418.38 Close: 415.51 Change: -2.87
Read more →Open: 415.01 Close: 416.5 Change: 1.49
Read more →Open: 408.16 Close: 410.68 Change: 2.52
Read more →Open: 354.95 Close: 353.04 Change: -1.91
Read more →Open: 379.64 Close: 376.2 Change: -3.44
Read more →Open: 357.15 Close: 357.45 Change: 0.3
Read more →Open: 351.26 Close: 348.9 Change: -2.36
Read more →Open: 350.0 Close: 358.4 Change: 8.4
Read more →Open: 349.91 Close: 350.87 Change: 0.96
Read more →Open: 329.82 Close: 325.3 Change: -4.52
Read more →Open: 341.37 Close: 343.2 Change: 1.83
Read more →